Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William J. Pao, Juliann Chmielecki · Nature reviews. Cancer · 2010
Cited by 1,073 works. doi:10.1038/nrc2947
Authors
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- UCSF Chimera—A visualization system for exploratory research and analysis
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Mutations of the BRAF gene in human cancer
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Cancer Statistics, 2009
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer